| Title : Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes - Rungby_2009_Expert.Opin.Investig.Drugs_18_835 |
| Author(s) : Rungby J |
| Ref : Expert Opin Investig Drugs , 18 :835 , 2009 |
| Abstract : BI 1356, a xanthine-based DPP-4 inhibitor, has reached Phase III trials. The compound efficiently inhibits dipeptidyl peptidase 4 (DPP-4) in vitro and in vivo. In vivo GLP-1 levels increase to levels at or above the levels of other DPP-4 inhibitors. Preclinical trials suggest a once-daily administration of 5 mg to be efficient, long-lasting and without known side effects. |
| ESTHER : Rungby_2009_Expert.Opin.Investig.Drugs_18_835 |
| PubMedSearch : Rungby_2009_Expert.Opin.Investig.Drugs_18_835 |
| PubMedID: 19426127 |
Rungby J (2009)
Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes
Expert Opin Investig Drugs
18 :835
Rungby J (2009)
Expert Opin Investig Drugs
18 :835